Design of small-molecule active-site inhibitors of the S1A family proteases as procoagulant and anticoagulant drugs
Vitamin K antagonists (VKA) have long been the default drugs for anticoagulant management in venous thrombosis. While efficacious, they are difficult to use due to interpatient dose–response variability and the risks of bleeding. The approval of fondaparinux, a heparin-derived factor Xa (fXa) inhibi...
| Main Author: | |
|---|---|
| Format: | Article |
| Published: |
American Chemical Society
2017
|
| Online Access: | https://eprints.nottingham.ac.uk/48039/ |